Skip to main content

Table 1 Demographics and baseline characteristics with and without MOa

From: The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study

  CM With MO CM Without MO
  Fremanezumab   Fremanezumab  
  Quarterly (n = 201) Monthly (n = 198) Placebo (n = 188) Quarterly (n = 174) Monthly
(n = 177)
Placebo
(n = 183)
Age, mean (SD), y 44.6 (11.6) 44.8 (10.9) 45.0 (10.8) 39.0 (12.6) 36.2 (11.5) 37.7 (12.1)
Sex, female, n (%) 183 (91) 173 (87) 168 (89) 147 (84) 154 (87) 158 (86)
BMI, mean (SD), kg/m2 26.4 (5.3) 26.4 (5.0) 26.0 (5.0) 26.9 (5.5) 26.7 (5.3) 26.9 (5.1)
Disease history
 Years since initial migraine diagnosis, mean (SD) 21.0 (12.7) 22.8 (12.3) 23.2 (13.8) 18.3 (12.9) 17.1 (11.0) 16.7 (11.0)
 Current preventive medication use, n (%) 47 (23.4) 54 (27.3) 38 (20.2) 30 (17.2) 31 (17.5) 39 (21.3)
 Current use of triptans or ergots, n (%) 141 (70.1) 138 (69.7) 128 (68.1) 67 (38.5) 49 (27.7) 64 (35.0)
 Prior topiramate use, n (%) 65 (32.3) 72 (36.4) 77 (41.0) 41 (23.6) 43 (24.3) 40 (21.9)
 Prior onabotulinumtoxinA use, n (%) 38 (18.9) 34 (17.2) 32 (17.0) 28 (16.1) 16 (9.0) 17 (9.3)
Disease characteristics during the 28-day pretreatment period
 Number of headache days of at least moderate severity,b mean (SD) 15.5 (5.0) 14.9 (5.4) 14.8 (5.4) 10.5 (4.8) 10.5 (5.3) 11.7 (5.8)
 Number of migraine days,c mean (SD) 17.2 (4.6) 17.5 (4.9) 17.3 (5.0) 15.0 (4.9) 14.3 (5.0) 15.4 (5.1)
 Number of days of acute medication use, mean (SD) 18.1 (4.0) 18.4 (4.5) 18.2 (4.4) 7.4 (4.4) 7.1 (4.5) 7.7 (4.5)
 HIT-6 score, mean (SD) 64.5 (5.1) 65.3 (4.4) 63.8 (5.2) 64.0 (4.3) 63.9 (4.3) 64.3 (4.4)
 PHQ-9 score, mean (SD) 4.3 (5.5) 5.9 (6.7) 3.7 (5.7) 4.1 (5.6) 4.0 (5.6) 4.0 (5.6)
MSQoL domain scores
 RFR, mean (SD) 49.1 (18.9) 46.8 (19.7) 49.7 (20.5) 48.2 (18.3) 49.7 (18.7) 48.8 (19.2)
 RFP, mean (SD) 67.5 (21.1) 63.2 (23.5) 67.5 (22.9) 67.1 (20.4) 68.7 (20.6) 67.4 (21.7)
 EF, mean (SD) 58.4 (26.2) 54.3 (27.1) 58.0 (27.5) 55.8 (26.9) 60.4 (25.1) 57.7 (25.4)
  1. BMI Body mass index, CM Chronic migraine, EF Emotional function, HIT-6 Six-item Headache Impact Test, MO Medication overuse, MSQoL Migraine-Specific Quality of Life, RFP Role function−preventive, RFR Role function−restrictive, SD Standard deviation
  2. aMO was defined as use of acute headache medication on ≥ 15 days, migraine-specific acute medication on ≥ 10 days, or combination medication for headache on ≥ 10 days during the 28-day pretreatment period. bA headache day of at least moderate severity was defined as a calendar day in which headache pain lasted at least 4 consecutive hours and had a peak severity of at least a moderate level, or a day in which acute migraine-specific medication (triptan or ergot) was used to treat a headache of any severity or duration. cA migraine day was defined as a calendar day in which headache pain lasted at least 4 consecutive hours and met criteria for migraine (with or without aura) or probable migraine (subtype in which only one migraine criterion is absent), or a day in which acute migraine-specific medication (triptan or ergot) was used to treat a headache of any duration.